Introduction
============

Population health scientists aim to understand disease patterns and develop approaches for disease prevention, detection, and diagnosis at an early stage to reduce the burden of disease \[[@r1]\]. Within the last decade there has been a rapid increase in the availability of health care data and never before have population scientists had the capacity to collect, share, and analyse data as they have today. Population health researchers often collect data from patients directly or from their health service records. Personal health records (PHRs) of patients contain a wealth of information, but can be challenging to analyse \[[@r2]\]. There is a variety of paper and electronic medical records (EMRs) in use, despite ongoing attempts to standardise data collection and a variety of clinical coding systems implemented by EMR vendors \[[@r3]\]. Terminologies and terminological systems play an important role in many medical information processing environments, giving rise to the "big knowledge" challenge, when terminological content comprises of tens of thousands to millions of concepts arranged in a non-relational manner \[[@r4]\]. The science of bioinformatics can provide essential tools and a framework for population scientists to manage this potentially overwhelming amount of data \[[@r1]\].

The challenge for Health Information Technology is to design systems that are powerful enough not only to handle the volume and complexity of medical data, but also to support both patients and professionals, resulting in improved health care, reduced costs and health outcomes for patients \[[@r2]\]. Data standardization and harmonization can address some of the obstacles to data sharing and pooling \[[@r3]\] \[[@r5]\] \[[@r6]\] \[[@r7]\]. Data harmonization is used when data standardization is not possible to achieve interoperability across systems. This work is laborious and entails a trans- disciplinary approach wherein informaticists, measurement and topical experts, biostatisticians, and ethicists combine their knowledge to ensure the integrity and security of harmonized data \[[@r5]\] \[[@r6]\]. One method applied to harmonise terminology is the abstraction network.

An abstraction network overlays a terminology's underlying network structure at a higher level of abstraction. In particular, it provides a more compact view of the terminology's content, avoiding the display of minutiae \[[@r4]\]. The notion of an abstraction network is presented as a means of facilitating the usability, comprehensibility, visualization, and quality assurance of terminologies \[[@r8]\]. One very important feature of an abstraction network is that it is typically multiple orders of magnitude smaller in size than its underlying terminology. This compact structure makes abstraction networks much more manageable from visualization and comprehension perspectives \[[@r9]\]. The reduction in size of an abstraction network is obtained by structurally dividing a large terminology into smaller parts, each of which is represented by one constituent entity (node) of the abstraction network \[[@r4]\].

There are two main ways to define the set of nodes of an abstraction network, intrinsic and extrinsic. Intrinsic abstraction networks derive them from the concepts and relationships of the underlying terminology itself. That is, some terminology concepts are of a general nature and can be used to properly categorize other elements \[[@r4]\]. Another alternative for choosing nodes is by a domain expert gleaning broad categories, befitting the terminology's subject matter, from external sources \[[@r4]\]. For example, the categories might be taken from the general body of literature in a subject area or from a standard reference work. An abstraction network derived in this way from sources external to the terminology itself is called extrinsic. For example, for a terminology in the medical field, broad categories could be disease, laboratory test, and procedure. Extrinsic networks do put a burden on the designer in terms of determining the level of refinement \[[@r4]\].

The aim of this study was to map medication data retrieved from individual patient health records for population health researcher's use through the use of an abstraction network to create a compact and more easily understandable view for public health research.

Methods
=======

The modelling of medication data within PHReDMS was based on the Monthly Index of Medical Specialties (MIMS) \[[@r10]\]. In Australia MIMS is commonly used to define independent medicine information used by Australian healthcare professionals. Medications within MIMS are classified by:

1.  \- The body system for which the medicine is used, e.g. cardiovascular system

2.  \- Medication class, e.g. beta-adrenergic blockers

3.  \- Medication subcategory, e.g. rapid acting (under insulins)

4.  \- Route, e.g. inhaled, topical, anorectal

5.  -Medication brand & generic name

Medications within patient records are often recorded with both Brand and Generic names being used interchangeably during the prescribing process. Whilst a category of medication may have utility across multiple medical conditions, MIMS medication subcategories are made up of drugs that are similar in terms of both function and formulation. The formulation of any given medication, in terms of its constituent compounds and their function, remains similar regardless of pharmaceutical producer, brand or generic naming. For example, beta blockers are a subcategory of anti-hypertensive drugs. Atenolol (brand names include Noten & Tenormin) and propranolol (commonly branded as Apo-Propranolol) are both beta blockers. The active ingredient in atenolol is always a benzacetamide compound named atenolol, and in propranolol it is propranolol hydrochloride. Both compounds/ active ingredients exert a therapeutic effect by blocking beta adrenergic receptors. For research purposes, we might want to analyse data at the level of beta receptor blockers, or at anti-hypertensives, or even at a higher level of all drugs that exert an action upon the cardiovascular system.

A working group comprising of a database administrator, a three person database development team, two researchers and a principal investigator met on an as needed basis to develop the medications mapping model. The researchers were qualified general medical practioners, who have a number of years of experience with patient medical record information. An electronic extract of medications from a clinical information system was compared to the MIMS database by the researchers. After primary classification of brand and generic medications by the researchers, the working group utilised an iterative process over multiple meetings to clarify the mapping. Medications within the PHReDMS were mapped based on active ingredients/constituent compounds (See [Table 1](#t1){ref-type="table"} for an example). By basing categorisation on the common constituent compounds (often listed in the generic medication name) instead of nomenclature (brand or generic medication names), the working group were able to map medication into subcategories and categories to enable analysis on multiple levels from a single data collection, as well as aid categorisation of data from varied sources.

###### Medication Mapping Model in PHReDMS

  ---------------------- ----------------------------------- ---------------------------- ---------------------------- ------------------------------
  **Brand name**         **Generic name/ active compound**   **Function**                 **Medication subcategory**   **Medication category**
  Apo carvedilol         carvedilol                          Non selective beta blocker   Beta blocker                 Anti-hypertensive medication
  Dilatrend              carvedilol                          Non selective beta blocker   Beta blocker                 Anti-hypertensive medication
  Coveram                amlodipine                                                       Calcium channel blocker      Anti-hypertensive medication
  Perindopril arginine   ACE inhibitor                                                                                 
  ---------------------- ----------------------------------- ---------------------------- ---------------------------- ------------------------------

Medications within the PHReDMS are mapped based on active ingredients/constituent compounds ([Table 1](#t1){ref-type="table"}). The MIMS database was used to link generic and brand names to active ingredients, with generic names often mirroring the active ingredient present. PHReDMS does not store the name of branded drugs, it only stores the ingredients. A custom built sql script extracting as many ingredients as are listed against the branded drug in Communicare. This was usually no more than three active ingredients. The PHReDMS attaches an active ingredient to any number of subcategories. Subcategory descriptors relate either to function or route of administration. Categories can be constituted of multiple subcategories and multiple categories can be used to treat a particular health condition. An exception column exists to detail any medications that deviate in function from the rest of their class.

Medication categories recorded in PHReDMS were examined, with medications focused to the major medication classes and of interest to the research group. However this model can be scaled to include more categories of medication as required. Each medication category contains an Other subcategory, to classify any new medications that do not fall into pre-existing subcategories. There is also an overall Other category, to classify any medications extracted that do not fall into the limited categories as defined in PHReDMS. New medications which fall into existing subcategories or categories can be added by the researcher forwarding their details to the database administrator.

Results
=======

Initially there were 7416 medications extracted from the Communicare from which were derived a list of 601 compounds. These compounds were then mapped into 63 sub-categories and 19 categories. Nutritional supplements have been collapsed to just their generic compounds as they are primary data for the researchers using the PHReDMS ([Table 2](#t2){ref-type="table"}).

###### Medication Categories Recorded in The Public Health Research Data Management System.

  --------------------------- -------------------------------------------------------------------- ------------------------- -----
                                                                                                                             
  **Category**                **Subcategory**                                                                                
  **Full name**               **Full name**                                                        **Abbreviation**          
  Insulins                                                                                                                   
                              Short acting insulins                                                Short                     
                              Long acting insulins                                                 Long                      
                              Intermediate acting insulins                                         Intermediate              
                              Rapid acting insulins                                                Rapid                     
                              Mixed insulins                                                       Mixed                     
  Oral hypoglycaemic agents                                                                                                  
                              Biguanides                                                                                     
                              Sulphonylureas                                                                                 
                              Thiazolidinediones                                                                             
                              Alpha-glucosidase inhibitors                                                                   
                              Meglitinides                                                                                   
                              Dipeptidyl peptidase-4 inhibitors                                    DPPIs                     
  Antihypertensives                                                                                                          
                              Beta blockers                                                        B-blockers                
                              Angiotensin Converting Enzyme inhibitors                             ACE Inhibitors            
                              Calcium channel blockers                                             Ca channel blockers       
                              Centrally acting antihypertensive agents                             Centrally acting          
                              Sympatholytics                                                                                 
                              Other Antihypertensives                                                                        
                              Angiotensin 2 receptor antagonists                                   A2 antagonists            
  Vasodilators                                                                                                               
                              Nitrates                                                                                       
                              Other Vasodilators                                                                             
  Diuretics                                                                                                                  
                              Thiazides                                                                                      
                              Potassium sparing diuretics                                          K+                        
                              Other diuretics                                                                                
                              Loop diuretics                                                       Loop                      
  Antiarrhythmics                                                                                                            
                              Class I                                                                                        
                              Class IA                                                                                       
                              Class IB                                                                                       
                              Class IC                                                                                       
                              Class II                                                                                       
                              Class III                                                                                      
                              Class IV                                                                                       
                              Class V                                                                                        
  Antibiotics                                                                                                                
                              Penicillins                                                                                    
                              Macrolides                                                                                     
                                                                                                   Quinolones                
                                                                                                   Rheumatic Heart disease   RHD
                                                                                                   Other antibiotics         
  Nutritional Supplements                                                                                                    
                              Fatty acids                                                                                    
                              Vitamins                                                                                       
                              Minerals                                                                                       
                              Other supplements                                                                              
                              Folates & derivatives                                                Folates                   
  Vaccines                                                                                                                   
  Urinary Acidifiers                                                                                                         
  Urinary Alkalinisers                                                                                                       
                                                                                                                             
  Hypolipidaemics                                                                                                            
                              Serum cholesterol reductors                                                                    
                              3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors   HMG CoA inhibitors        
                              Fibrates                                                                                       
                              Intestinal absorption inhibitors                                                               
                              Bile acid sequestrants                                                                         
                              Other hypolipidaemics                                                                          
  Anticoagulants                                                                                                             
                              Anti Factor Xa                                                                                 
                              Antiplatelet aggregation                                                                       
                              Antithrombotic                                                                                 
                              Thrombin Inhibitors                                                                            
                              Coumarins                                                                                      
                              Superfiial thromboses                                                                          
                              Other anticoagulants                                                                           
  Antifungals                                                                                                                
  Corticosteroids                                                                                                            
                              Glucocorticoids                                                                                
                              Mineralcorticoids                                                                              
                              Other corticosteroids                                                                          
  Alpha blockers                                                                                                             
  Anti-asthmatics                                                                                                            
                              Beta2 agonists                                                                                 
                              Anticholinergics                                                                               
                              Inhaled corticosteroids                                                                        
                              Other bronchodilators                                                                          
  Anaesthetics                                                                                                               
  Other                                                                                                                      
  --------------------------- -------------------------------------------------------------------- ------------------------- -----

Discussion
==========

One way to confront the "big knowledge" challenge is to provide auxiliary support structures to aid in terminology use and maintenance \[[@r4]\]. Highly interactive partially-automated mapping tools that are directed by human input to automate parts of the mapping process, with specific expert input, are a promising alternative to fully automated methods \[[@r11]\]. In this study we were able to successfully use an abstraction network to map medication data from patient electronic medical records. This enables patient information to be easily utilised by population health researchers.

Patient health information is largely stored in EMRs, which are used by most health care providers for the regular documentation of care provided. Administrators also use EMRs for purposes of reporting upon and monitoring activities in health facilities. Whilst some patient data is still stored in paper format, researchers are increasingly asking to access EMR data for the purposes of population level research, including the development of clinical decision support tools. The vast amounts and complexity of information within EMRs complicates information management for each of these groups and increases the risk of incorrect decisions being made due to the difficulties of sifting through so much information. Likewise with paper records, the amount, variability and complexity of information stored within them makes it difficult to collect and analyse this data in a reliable manner. Managing medications data is a particular challenge; as the burden of chronic disease increases in the population \[[@r12]\] so do issues related to polypharmacy and its management \[[@r13]\] \[[@r14]\] \[[@r15]\]. Clinicians and researchers need new tools to manage medication- related information. Although there can be an overwhelming number of medications and medicine classes prescribed per patient, pharmacology is relatively structured when it comes to classification of the active ingredients or constituents of medication. Additionally, various therapeutic guidelines are available that are already in use in practice to thoroughly document and categorise medication, ensuring relatively easy access to the expert opinions required to inform any medications mapping.

For research purposes, data is sourced from various EMRs and paper patient files, which capture medications data related to MIMS in different formats. A research database like PHReDMS needs to be flexible enough to contain medications data;

1.  From various sources, which may or may not be inter-relatable

2.  Across various topics, which are externally set by researchers accessing the database

3.  That reflects changes over time

Limitations
===========

The development of the abstraction network to manage medication records for individual patient's for chronic disease management research has been extremely labour intensive. The abstraction network requires updating before new patient records are added to an individual research project to capture new medications that have been recently released into the population.

Conclusion
==========

Mapping in the manner described above has enabled data to be categorised to allow researchers to query and analyse it at multiple levels (disease grouping, category, subcategory, and compound) relevant to their particular research question, without compromising the richness of individual level medications data. It allows all data collected by various researchers from various sources to be aggregated into one database, thus providing a valuable source of population level data. The mapping process is geared towards population level chronic diseases medication data, and will need to be expanded for uses outside of this scope (e.g oncology) however the system is flexible enough to enable this as may be required in the future.
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